Skip to main content
. 2019 Jan 16;14(1):e0210647. doi: 10.1371/journal.pone.0210647

Table 1. Published series reporting Snellen visual acuity in eyes with retinoblastoma.

Included series were published 2006 or later (concurrent with our study population), listed in order of cohort size (RE = Reese-Ellsworth classification).

Authors Publication Primary treatment Number of eyes Classification Enucleation % 20/40 or greater % 20/50 to 150 % Poor vision Fix/Follow Follow-up (months)
Levin et al (present) OAC 157 ICRb D or E 39 (25%) 19 (12%) 5 (3%) 133 (85%, 20/200 or worse) NA 51
Levin et al (present) OAC 63 Unilateral ICRb D or E with macular disease 11 (17%) 4 (6.3%) 1 (1.5%) 58 (92%) NA  
Levin et al (present) OAC 18 Unilateral ICRb D or E with no macular disease 4 (22%) 5 (28%) 1 (5.6%) 12 (67%) NA  
Berry et al Pediatr Blood Cancer. 2013 Apr;60(4):688–93. IVC plus EBR 62 ICRb D 17 (27%), included 5 (8.1%) 6 (8.3%) 31 (50%, 20/200 or worse) 20 (32%) 54.2
Berry et al Br J Ophthalmol. 2014 Aug;98(8):1061–5. IVC plus EBR 52 ICRb D Enucleation excluded 5 (9.6%) 12 (23%) 25 (71%; worse than 20/200) 10 (19%) 50
Shields et al Ophthalmology. 2009 Mar;116(3):544-551.e1 IVC 38 ICRb E Enucleation excluded 4 eyes (11%, 20/50 or better) 11 (29%, 20/60 to 20/100) 21 (55%, 20/200 or worse) 2 (5.3%) 63
Choi et al J Korean Med Sci. 2010 Apr;25(4):546–51. EBR 32 RE II-V 8 (25%), included 9 (28%) 5 (16%) 18 (56%, 20/200 or worse) NA 150
Fabian et al Am J Ophthalmol. 2017 Jul;179:137–144. IVC plus adjuvent 32 ICRb D Enucleation excluded 7 (22%) 9 (28%) 16 (50%, worse than 20/200)a NA 64.4
Rao et al Br J Ophthalmol. 2018 Apr;102(4):490–495. Intravit. injection 17 ICRb C and D 1 (5.8%), included 6 (35%) 5 (29%) 5 (29%, 20/200 or worse) NA 23.8
Schefler et al Ophthalmology. 2007 Jan;114(1):162–9. IVC and laser 14 RE I-V Enucleation excluded 5 (36%) 3 (21%) 6 (43%, 20/200 or worse) NA 36
Authors Publication Primary treatment Number of eyes Classification Enucleation % 20/40 or greater % 20/50 to 150 % Poor vision Fix/Follow Follow-up (months)
Kim et al Korean J Ophthalmol. 2010 Dec;24(6):347–52. IVC plus local 13 ICRb B Enucleation excluded 5 (38%) 2 (15%) 6 (46%, 20/200 or worse) NA 79.3
Tsimpida Br J Ophthalmol. 2013 Nov;97(11):1464–70. IAM 12 (excluded eyes with foveolar disease) 0 (0%) 6 (50%) 1 (8.3%) 4 (33%, 20/200 or worse) 1 (8.3%) 21
Jung et al J Pediatr Hematol Oncol. 2018 Apr 20. Proton beam rad. 4 ICRb D 2 (50%), included 1 (25%) 0 (0%) 3 (75%, 20/200 or worse) NA 12; 50

a This number was calculated by the authors of the present study from the numbers reported in the published study.